MDS Pharma Services

Cetero says FDA’s actions ‘difficult to understand’—company notified agency of chemists’ misconduct

Monday, August 1, 2011 08:02 AM

Large, early-phase CRO Cetero Research seemed blindsided by the FDA’s letter to the company last week accusing it of falsifying data and manipulating samples over a five-year period at its Houston bioanalytics lab.

More... »

Czura Thornton to Buy MDS Central Lab Business

Monday, October 19, 2009 07:46 AM

Czura Thornton, the private investment group that already owns UK-based contract research organization (CRO) Chiltern International, has agreed to acquire the global central laboratory operations of MDS Pharma Services for about $8 million. 

More... »

Brazil Certifies MDS Pharma Services Early Clinical Facilities

Thursday, October 8, 2009 08:46 AM

MDS Pharma Services’ early clinical research and clinical pharmacology operations in Belfast, Northern Ireland, and its clinical pharmacology and bioanalytical services operation in Lincoln, Nebraska, have been certified by Brazil’s regulatory agency, Agencia Nacional de Vigilancia Sanitaria (ANVISA).

More... »

LabConnect Hires Former Quintiles Exec to be COO

Friday, August 28, 2009 07:32 AM

LabConnect, a provider of central laboratory services to the clinical trial industry, appointed former Quintiles executive Frank Morrow, Ph.D., as its chief operating officer.

More... »

Covance, MDS Pharma Earn MHRA Accreditation

Thursday, August 13, 2009 08:21 AM

Covance and MDS Pharma Services both recently earned standard and supplementary accreditation for the conduct of clinical pharmacology in Europe by the Medicines and Healthcare products Regulatory Agency (MHRA).

More... »

MDS Pharma's First Quarter Revenues Down 12%

Friday, March 13, 2009 08:00 AM

Revenues for contract research organization (CRO) MDS Pharma Services continue to fall as a result of client delays in late-stage research and decreased activity in preclinical and bioanalytical services.

More... »

MDS Pharma Profits Sink in 3rd Quarter

Thursday, September 4, 2008 01:33 PM

Canadian life science company MDS, the parent company of King of Prussia, Pa.-based CRO MDS Pharma Services, reduced its fiscal 2008 revenue and profit outlook after reporting lower than expected third-quarter results in its contract research division. The company now expects fiscal 2008 revenue to be in the range of $1.23 billion to $1.25 billion, down from its previous forecast of $1.25 billion to $1.29 billion.

More... »

MDS Cuts 210 Staff in North America

Friday, July 18, 2008 01:45 PM

MDS has become the second pharmaceutical services company in as many weeks to report a round of layoffs. Toronto-based MDS has slashed 210 jobs from its North American workforce, representing 4% of MDS’s 5,500 worldwide employees. The company stated that 75% of the lay offs will come from its MDS Pharma Services (contract research) division with the remainder from its Analytical Technologies (medical equipment manufacturing) group. MDS cited that the action will result in third quarter charges of $18 million and $10 million in write downs at its Pharma Services laboratory based in Montreal. Company shares rose 1.8 per cent, or 26 cents, to $14.85 in trading on the Toronto Stock Exchange.  MDS is scheduled to release its third quarter fiscal 2008 earnings on September 4, 2008.

More... »